Acrobiosystems Co

Acrobiosystems Co Market Cap per Employee

The Market Cap per Employee of Acrobiosystems Co (301080.SZ) as of Nov 11, 2026 is 16.49 M CNY. In the previous year, Market Cap per Employee was 16.49 M CNY — a change of 0.00% (lower).

Market Cap per Employee

16.49 MCNY

YoY

0.00%

Last updated:

Market Cap per Employee of Acrobiosystems Co is 2025 16.49 M CNY. Market Cap per Employee of Acrobiosystems Co was 2024 16.49 M CNY. It decreases by 0.00% lower compared to the previous year.

The Acrobiosystems Co Market Cap per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Market Cap per Employee
Date
Market Cap per Employee
Jan 1, 2018
16.49 M CNY
Jan 1, 2019
16.49 M CNY
Jan 1, 2020
16.49 M CNY
Jan 1, 2021
16.49 M CNY
Jan 1, 2022
16.49 M CNY
Jan 1, 2023
16.49 M CNY
Jan 1, 2024
16.49 M CNY
Jan 1, 2025
16.49 M CNY
The Acrobiosystems Co Market Cap per Employee history
YEARMarket Cap per EmployeeYoY
16.49 MCNY0.00%
16.49 MCNY0.00%
16.49 MCNY0.00%
16.49 MCNY0.00%
16.49 MCNY0.00%
16.49 MCNY0.00%
16.49 MCNY0.00%
16.49 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Acrobiosystems Co Stock analysis

What does Acrobiosystems Co do? Acrobiosystems Co Ltd develops biomedicine and bio-protein technology, focusing on recombinant proteins, detection services, kits, antibodies, fillers, and culture media. The company serves R&D and production sectors for drug discovery, screening, diagnostic reagents, and clinical trials across tumor, autoimmune, cardiovascular, and infectious disease areas. Its products support early drug development stages and process control in pharmaceutical manufacturing. The firm's main customers are pharmaceutical companies and research institutions requiring advanced biotech solutions for disease treatment development. The company generates revenue through the sale of recombinant proteins, detection services, and related products like kits and antibodies. These offerings are tailored for pharmaceutical firms engaged in drug development and diagnostic reagent optimization. Acrobiosystems' product portfolio targets the biopharmaceutical industry, specifically addressing needs in tumor, autoimmune, cardiovascular, and infectious disease research. The firm's services are utilized in preclinical and clinical trial phases to enhance drug development efficiency. Acrobiosystems' main products include recombinant proteins, kits, antibodies, fillers, and culture media, which are sold to pharmaceutical companies and research organizations. These entities use the products for early-stage drug discovery, verification, and optimization processes. The company's detection services support diagnostic reagent development and drug screening, directly contributing to the pharmaceutical R&D pipeline. The firm's focus on CMC (process control) for drug production ensures its offerings align with critical manufacturing stages in biopharmaceutical development. Acrobiosystems Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Acrobiosystems Co stock

Market Cap per Employee of Acrobiosystems Co is 16.49 M CNY in 2025.

Market Cap per Employee of Acrobiosystems Co changed from 16.49 M CNY to 16.49 M CNY, representing a 0.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Market Cap per Employee Acrobiosystems Co since 2006 – with annual values, charts, and detailed analysis.

Market cap per employee shows the market value attributed to each employee. Technology companies typically have higher values due to intellectual capital.

Market Cap per Employee's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Market Cap per Employee's Acrobiosystems Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Acrobiosystems Co

All Key Metrics — Acrobiosystems Co